• Jazz Pharmaceuticals priced an upsized private offering of USD 1.1 billion 1.875% exchangeable senior notes due 2032.
• Deal increased from the previously announced USD 1 billion; initial purchasers hold an option for up to USD 150 million more.
• Net proceeds estimated at about USD 1.08 billion, or about USD 1.23 billion if the option is exercised in full.
• Offering expected to close Aug. 31, 2026; proceeds earmarked for general corporate purposes.
• Concurrent with pricing, the company repurchased about USD 225 million of ordinary shares at USD 249.29 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608270030PR_NEWS_USPR_____SF34937) on August 27, 2026, and is solely responsible for the information contained therein.